TY - JOUR
T1 - Cyclosporine/methotrexate versus tacrolimus/methotrexate with or without anti-thymocyte globulin as GVHD prophylaxis in adult patients with aplastic anemia
AU - on behalf of the Adult Aplastic Anemia Working Group of the Japan Society for Hematopoietic Cell Transplantation
AU - Onishi, Yasushi
AU - Mori, Takehiko
AU - Yamazaki, Hirohito
AU - Takenaka, Katsuto
AU - Yamaguchi, Hiroki
AU - Shingai, Naoki
AU - Ozawa, Yukiyasu
AU - Iida, Hiroatsu
AU - Ota, Shuichi
AU - Uchida, Naoyuki
AU - Miyamoto, Toshihiro
AU - Katayama, Yuta
AU - Kato, Jun
AU - Yoshioka, Satoshi
AU - Onizuka, Makoto
AU - Ichinohe, Tatsuo
AU - Atsuta, Yoshiko
N1 - Funding Information:
The authors thank all of the clinical physicians and staff members at the collaborating transplantation centers, the JSHCT, the Japan Marrow Donor Program, and the Japanese Data Center for Hematopoietic Cell Transplantation.
Funding Information:
This work was financially supported in part by the Practical Research Project for Allergic Diseases and Immunology (Research Technology of Medical Transplantation) from the Japan Agency for Medical Research and Development (AMED) under grant 18ek0510023h0002. Acknowledgments
Publisher Copyright:
© 2020, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2021/1
Y1 - 2021/1
N2 - The impact of calcineurin inhibitor types and anti-thymocyte globulin (ATG) in conditioning on overall survival (OS) and GVHD-free, relapse-free survival (GRFS) has not yet been analyzed in detail for aplastic anemia. We herein examined 517 adult patients with aplastic anemia who underwent BMT from HLA-matched sibling donors (MSD, n = 255) and unrelated donors (UD, n = 262) and were treated with cyclosporine A (CSA) + methotrexate (MTX) (n = 258) and tacrolimus (TAC) + MTX (n = 259). In total, 330 patients received ATG in conditioning. CSA + MTX versus TAC + MTX did not have a significant impact on acute and chronic GVHD, OS, or GRFS in each donor type. The use of ATG in conditioning reduced the risk of grade II–IV acute GVHD in the MSD and UD cohorts (HR 0.42, P = 0.014, and HR 0.3, P < 0.001, respectively); however, a differential impact on GRFS was identified, namely, better GRFS in MSD recipients (HR 0.56, P = 0.016), but not in UD recipients (HR 1.1, P = 0.657). In conclusion, CSA + MTX and TAC + MTX were similar as GVHD prophylaxis regardless of the donor type, and ATG in conditioning increased GRFS in MSD transplants, but not in UD transplants.
AB - The impact of calcineurin inhibitor types and anti-thymocyte globulin (ATG) in conditioning on overall survival (OS) and GVHD-free, relapse-free survival (GRFS) has not yet been analyzed in detail for aplastic anemia. We herein examined 517 adult patients with aplastic anemia who underwent BMT from HLA-matched sibling donors (MSD, n = 255) and unrelated donors (UD, n = 262) and were treated with cyclosporine A (CSA) + methotrexate (MTX) (n = 258) and tacrolimus (TAC) + MTX (n = 259). In total, 330 patients received ATG in conditioning. CSA + MTX versus TAC + MTX did not have a significant impact on acute and chronic GVHD, OS, or GRFS in each donor type. The use of ATG in conditioning reduced the risk of grade II–IV acute GVHD in the MSD and UD cohorts (HR 0.42, P = 0.014, and HR 0.3, P < 0.001, respectively); however, a differential impact on GRFS was identified, namely, better GRFS in MSD recipients (HR 0.56, P = 0.016), but not in UD recipients (HR 1.1, P = 0.657). In conclusion, CSA + MTX and TAC + MTX were similar as GVHD prophylaxis regardless of the donor type, and ATG in conditioning increased GRFS in MSD transplants, but not in UD transplants.
UR - http://www.scopus.com/inward/record.url?scp=85092183557&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092183557&partnerID=8YFLogxK
U2 - 10.1007/s00277-020-04290-1
DO - 10.1007/s00277-020-04290-1
M3 - Article
C2 - 33033911
AN - SCOPUS:85092183557
SN - 0939-5555
VL - 100
SP - 217
EP - 228
JO - Annals of Hematology
JF - Annals of Hematology
IS - 1
ER -